NCT05782777View on ClinicalTrials.gov

Effect of High-intensity Statin With Ezetimibe COmbination theRapy Versus High-intensity sTatin Monotherapy After Percutaneous Coronary Intervention With Drug-eluting Stents; the ESCORT Trial

NARecruitingINTERVENTIONAL
Enrollment

4,310

Participants

Timeline

Start Date

April 7, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Coronary Artery Disease Requiring Coronary Revascularization With Newer Generation DES Implantation
Interventions
DRUG

ezetimibe/high-intensity statin combination therapy (ezetimibe 10mg plus atoravastatin 40mg)

The initial dose of lipid-lowering therapy will be ezetimibe 10mg plus atoravastatin 40mg. During follow-up, the dose of ezetimibe 10mg plus atoravastatin 40mg is strongly recommended to be maintained.

DRUG

high-intensity statin monotherapy (atoravastatin 40mg)

The initial dose of lipid-lowering therapy will be atoravastatin 40mg. During follow-up, the dose of atoravastatin 40mg is strongly recommended to be maintained.

Trial Locations (1)

Unknown

RECRUITING

Yonsei University Health System, Severance Hospital, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER